...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>European journal of neurology: the official journal of the European Federation of Neurological Societies >Patient-reported convenience of once-daily versus three-times-daily dosing during long-term studies of pramipexole in early and advanced Parkinson's disease
【24h】

Patient-reported convenience of once-daily versus three-times-daily dosing during long-term studies of pramipexole in early and advanced Parkinson's disease

机译：在长期和早期帕金森氏病研究中，患者报告的普拉克索长期研究期间，每日一次与每日三次给药的便利性

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background and purpose: In chronic diseases including Parkinson's disease (PD), complex pharmacotherapy dosing schedules are reported to reduce adherence, perhaps leading to less-effective symptom control and, in PD, more erratic stimulation of dopamine receptors. However, blinded clinical-trial designs preclude direct comparisons of adherence to various schedules. Methods: In two double-blind (DB) studies of early PD and one of advanced PD, subjects received three-times-daily (t.i.d.) pramipexole or placebo. In open-label (OL) extensions, subjects took extended-release, once-daily (q.d.) pramipexole. At 24 or 32 OL weeks, q.d. versus t.i.d. dosing preference was surveyed by questionnaire. Results: Of 590 DB-trial completers with early PD, 511 entered the OL extension. Of 374 survey respondents, 94.4% preferred q.d. dosing (72.2% of them found it 'very much more convenient' and 27.8%'more convenient'), 2.7% preferred t.i.d., and 2.9% chose 'no difference'. Of 465 DB-trial completers with advanced PD, 391 entered its OL extension. Of 334 survey respondents, 88.9% preferred q.d. dosing (59.9% of them found it 'very much more convenient' and 40.1%'more convenient'), 5.7% preferred t.i.d., and 5.4% chose 'no difference'. Results excluding DB-placebo recipients were highly similar. Conclusions: In this first direct comparison of patient preference for q.d. versus t.i.d. dopamine-agonist dosing, patients with early or advanced PD had a strong preference for q.d. rather than t.i.d. pramipexole. The high proportion of advanced-PD patients declaring this preference indicates that it does not depend on whether a patient is taking concomitant PD medications dosed more frequently than q.d.
机译：背景与目的：据报道，在包括帕金森氏病（PD）在内的慢性疾病中，复杂的药物治疗给药方案会降低依从性，可能导致症状控制效果不佳，而在PD中，多巴胺受体的刺激性会更加不稳定。然而，盲目的临床试验设计排除了对各种方案依从性的直接比较。方法：在两项关于早期PD和一项晚期PD的双盲（DB）研究中，受试者每天接受3次（t.i.d.）普拉克索或安慰剂治疗。在开放标签（OL）扩展中，受试者服用了每天一次（q.d.）普拉克索的缓释制剂。 OL第24或32周，第q.d.与t.i.d.通过问卷调查剂量偏好。结果：在590名具有早期PD的DB试验完成者中，有511名进入了OL扩展名。在374位受访者中，有94.4％的受访者较喜欢。给药（其中72.2％的人认为它``非常方便''，而27.8％的人更喜欢``t.i.d.''）和2.9％的人选择``没有差异''。在465种具有高级PD的DB试用完成程序中，有391种进入了OL扩展名。在334名受访者中，有88.9％的受访者较喜欢。给药（其中59.9％的人认为它``非常方便''，40.1％的人更方便），5.7％的首选t.i.d.和5.4％的人选择了'无差异'。排除DB-安慰剂接受者的结果非常相似。结论：在这直接比较患者对q.d的偏爱。与t.i.d.多巴胺受体激动剂的使用，PD早期或晚期的患者对q.d有强烈的偏好。而不是t.i.d.普拉克索。晚期PD患者中有很高比例的人表示偏好，这表明这并不取决于患者是否服用比q.d更为频繁的伴随PD药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号